Fosun Pharma's stock price fell on suspension of vaccination of two batches of new crown vaccine! The company responded urgently...

On the 24th, the Macao Coordination Center for Coordination of New Coronavirus Infections issued a notice indicating that the Macao Health Bureau has recently received a written notice from Fosun Industrial (Hong Kong) Co.

Screenshot of Macau SAR government announcement

Screenshot of the Hong Kong Special Administrative Region Government Announcement

According to previous reports in Hong Kong media, on February 27, 585,000 doses of the first batch of 1 million doses of Fupbitil vaccine were shipped from Germany to Hong Kong, and the remaining doses were shipped to Hong Kong in early March.

Renaissance emergency response to A+H shares double diving

Not long after, Fosun Pharma responded to the news that "mRNA new crown vaccine is covered with related defects, Hong Kong and Macao will suspend vaccination today.

Affected by this news, as of today's close, Fosun Pharma’s A shares fell 5.

It is understood that the mRNA new crown vaccine BNT162b2 mentioned in this announcement was first developed by Baintech, Germany.

In January and February of this year, BNT162b2 was approved for emergency use in Hong Kong, China and a special import license from the Health Bureau of Macau, China.

5 new crown vaccines have been listed in China

According to the previous press conference held by the State Council’s Joint Prevention and Control Mechanism on the safety and effectiveness of the new coronavirus vaccine, there are currently 5 vaccines in my country, namely:

Inactivated vaccine:

Sinopharm Zhongsheng Beijing Company's new coronavirus inactivated vaccine was approved for listing with conditions on December 31, 2020;

Kexing Zhongwei new coronavirus inactivated vaccine was approved for marketing with conditions on February 5, 2021;

Sinopharm Zhongsheng Wuhan Company's new coronavirus inactivated vaccine was approved for marketing conditionally on February 25, 2021.

Adenovirus vector vaccine:

The recombinant new coronavirus vaccine developed by CanSino Bio will be approved for marketing with conditions on February 25, 2021.

Recombinant protein vaccine:

The Institute of Microbiology of the Chinese Academy of Sciences and Anhui Zhifeilongke Co.

Yesterday, CanSinoBio issued an announcement on the Hong Kong Stock Exchange stating that the inhaled recombinant new coronavirus vaccine (type 5 adenovirus vector) developed in cooperation with the Institute of Bioengineering, Academy of Military Sciences, Academy of Military Sciences of the Chinese People’s Liberation Army obtained NMPA on March 22 Approval for clinical trials of drugs.

Although there is no direct evidence in the announcement issued by Fosun at midday to indicate whether the safety of this batch of products is at risk, under such fierce competition in the domestic vaccine approval market, whether Fosun Pharma’s voluntary recall will give it a later stage Relevant product research and development will bring uncertainties in China's approval, which remains to be seen.

Reference: "Fosun Pharma: Vaccines are suspended from use in Hong Kong and Macau and sealed up, and are highly responsible for product safety"